PFIZER U.S. CARDURA SALES ARE $75.3 MIL. IN 1993 WITH BPH INDICATION IN OFFING; PROCARDIA XL FOURTH QUARTER SALES DROP ATTRIBUTED TO INVENTORY CHANGES
Pfizer's U.S. sales of the alpha blocker Cardura increased by 56% to $75.3 mil. in 1993, Chief Financial Officer Henry McKinnell told a meeting of securities analysts Feb. 8 in New York City.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth